How to Keep Weight Off After GLP-1 Therapy
The data is clear: stop GLP-1s cold and most patients regain. Here's the evidence on maintenance protocols, microdosing, and the metabolic transition off therapy.
Weight regain is the single most discussed limitation of GLP-1 therapy. The STEP 4 extension showed that patients who stopped semaglutide after a year regained roughly two-thirds of their lost weight within 12 months. That is not a failure of the medication — it is a feature of obesity biology.
Why weight comes back
Obesity is a chronic disease of energy regulation. Removing the medication restores the baseline appetite drive and metabolic adaptation that produced the original weight gain. Treating obesity for 12 months and then stopping is biologically equivalent to treating hypertension for a year and stopping — the disease returns.
The maintenance protocol
The standard maintenance approach reduces the GLP-1 dose rather than discontinuing it. For semaglutide, patients often transition from 2.4 mg weekly to 0.5–1.0 mg weekly. For tirzepatide, from 10–15 mg to 2.5–5 mg. This preserves appetite regulation at a fraction of the dose and cost.
Microdosing as a maintenance strategy
A growing practice is to use sub-therapeutic doses — 0.125–0.25 mg of semaglutide weekly — for long-term metabolic support. Evidence here is largely observational, but the mechanism is sound and side effects are minimal at these doses.
The non-medication pillars
Maintenance depends on three behaviors built during the active phase: protein intake of 1.0–1.2 g/kg of goal body weight, resistance training 3+ days per week to preserve lean mass, and a sleep window of 7–9 hours. These are not optional add-ons; they are the structural foundation that maintenance medication supports.
When to consider stopping entirely
Some patients successfully discontinue GLP-1 therapy after 18–24 months of stable weight with consistent training and protein intake. Discontinuation should be slow — typically a 3-month taper — and accompanied by close monitoring of weight, hunger, and labs.
Sources & references
Peer-reviewed studies, clinical guidelines, and regulatory documents used to write this article.
- 1.Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325:1414-1425.— Journal of the American Medical Association, 2021.
- 2.Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553-1564.— Diabetes, Obesity and Metabolism, 2022.
How this article was written: Researched and drafted by the Valora Rx editorial team using current peer-reviewed literature and clinical practice guidelines from bodies including the Endocrine Society, AUA, NAMS, ACOG, and FDA. This article is informational and is not a substitute for individualized medical advice from your physician. Read our editorial standards →
